North America Chronic Cough Market is expected to reach US$ 3,944.89 Mn by 2027

Combination drug segment is expected to drive the growth of the North America chronic cough market by drug class

According to the latest study on ‘Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class, Route of Administration, Distribution Channel, and Country,’ the North America chronic cough market was valued at US$ 2,118.42 million in 2019 and is projected to reach US$ 3,944.89 million by 2027; it is expected to grow at a CAGR of 8.1% during 2020–2027. The report highlights the trends prevailing in the North America chronic cough market and the factors driving the market along with those that act as deterrents to its growth.

Based on drug class, the chronic cough market is segmented antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and other drug class. In 2019, the combination drug segment accounted for the largest share of the North America chronic cough market. The growth of the segment attributes to the to rising incidences of chronic cough, growing product developments to treat chronic cough are some of the primary factors contributing to the dominance of the segment in the North America chronic cough market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the North American region. The US ranks number one in the world. The novel coronavirus has infected more than 2.18 million people in the US. ~680 thousand people have recovered from the infection. The symptoms of the disease show cough and flu with headaches. Therefore, it is expected that the market for chronic cough is likely to have a positive impact in the following years. During the period of the pandemic, the demand for albuterol, a conventional asthma inhaler medication, has risen significantly in the US. Furthermore, aging population is expected to drive demand for chronic cough treatment is likely to offer significant opportunities for the growth of the North America chronic cough market.

Novartis AG, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc., Bayer AG, Mylan N.V., Amneal Pharmaceuticals, Inc., Cipla Inc., Reckitt Benckiser Group plc., Sun Pharmaceutical Industries Ltd,

Aurobindo Pharma Ltd are among the prominent players present in the chronic cough market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in Mar 2018 GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business. GSK will buyout Novartis 36.5% stake in their Consumer Healthcare Joint Venture for US$13 billion (£9.2 billion).

North America Chronic Cough Market, By Country, 2019 (%)

---

North America Chronic Cough Market to Grow at a CAGR of 8.1% to reach US$ 3,944.89 Million from 2020 to 2027

Download Free Sample

---

North America Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, and Other Drug Class); Route of Administration (Oral, Injections, Inhalation, and Other Route of Administration); Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy); and Country

The report segments the North America chronic cough market as follows:

By Drug Class

• Antihistamines
• Corticosteroids
• Decongestants
• Combination Drug
• Antibiotics
• Acid Blockers
• Other Drug Class

By Route of Administration

• Oral
• Injections
• Nasal
• Other Route of Administration

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Country

• US
• Canada
• Mexico